References
- Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117:84–92
- Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J 2000;19:822–7
- Weese-Mayer DE, Fondriest DW, Brouillette RT, Shulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987;6:190–6
- Manzoni P, Jacqz-Aigrain E, Rizzollo S, et al. Antifungal prophylaxis in neonates. Early Hum Dev 2011;87:S59–60
- Manzoni P, Farina D, Leonessa M, et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics 2006;118:2359–64
- Baley JE, Kliegman RM, Boxerbaum B, Fanaroff AA. Fungal colonization in the very low birth weight infant. Pediatrics 1986;78:225–32
- Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007;356:2483–95
- Clerihew L, Austin N, McGuire W. Systemic antifungal prophylaxis for very low birthweight infants: a systematic review. Arch Dis Child Fetal Neonatal Ed 2008;93:198–200
- Ozturk MA, Gunes T, Koklu E, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses 2006;49:484–92
- Aydemir C, Oguz SS, Dizdar EA, et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011;96:164–8
- Hope WW, Castagnola E, Groll AH, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012;18:38–52
- Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005;147:192–6
- Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008;122:693–700
- Oncel MY, Sari FN, Arayici S, et al. Lactobacillus reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2014;99:F110–15
- Oncel MY, Erdeve O, Dilmen U. Probiotics for necrotizing enterocolitis: not always a success story. J Pediatr. 2014;165:417
- Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol 2011;31:63–9
- Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of Candidiasis. Clin Infect Dis 2004;38:161–89
- Walsh MC, Kliegman RM, Fanaroff AA. Necrotizing enterocolitis: a practitioner’s perspective. Pediatr Rev 1988;9:219–26
- Howell A, Isaacs D, Halliday R. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed 2009;94:429–33
- Ganesan K, Harigopal S, Neal T, et al. Prophylactic oral nystatin for preterm babies under 33 weeks’ gestation decreases fungal colonization and invasive fungaemia. Arch Dis Child Fetal Neonatal Ed 2009;94:275–8
- Karvonen A, Casas I, Vesikari T. Safety and possible antidiarrhoeal effect of the probiotic Lactobacillus reuteri after oral administration to neonates. Clin Nutr 2001;20:63. (abstract 216)
- Demirel G, Celik IH, Erdeve O, et al. Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. Eur J Pediatr 2013;172:1321–6